炎症性肠病药物联合治疗的获益与风险

Benefits and risks of drug combination therapy for inflammatory bowel disease

目前炎症性肠病(IBD)的发病机制未完全明确,虽有越来越多的生物制剂问世,但其治疗仍存在难点,有时无法得到令人满意的疗效。在临床实践中,当常规治疗收效不佳时,将几种药物联合应用治疗IBD不失为一种重要的治疗策略,但药物联合治疗提高疗效的同时可能会增加感染及肿瘤等风险。因此应用联合治疗时需结合患者的疾病类型、病情程度、病变范围、高危因素、既往用药情况,对治疗方案进行技巧性地选择和甄别必不可少。

At present,the pathogenesis of inflammatory bowel disease(IBD)is not completely clear.Although more and more biological agents are available,there are still difficulties in the treatment of IBD.In clinical practice,when conventional treatment is not effective,combining several drugs to treat IBD may be an important treatment strategy.But the combination of drugs may increase the risk of infection and tumor while improving the efficacy.Therefore,the application of combined therapy should be selected skillfully combined with the patient′s disease type,disease degree,lesion range,high risk factors and previous medication.